Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.
Climb Bio has raised $110.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
Climb Bio's investors include RA Capital Management, Cormorant Asset Management, Janus Henderson Investors, Adage Capital Management, Samsara BioCapital.
Climb Bio is headquartered in Redmond, United States.
Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.
Climb Bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Climb Bio — Funding & Investors." VCBacked, April 28, 2026, https://www.vcbacked.co/company/climb-bio. Accessed July 19, 2026.
VCBacked. (2026). Climb Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/climb-bio
{{cite web |title=Climb Bio — Funding & Investors |url=https://www.vcbacked.co/company/climb-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated